HIV Infection Clinical Trial
Official title:
A Test of an Intervention to Improve Pap Testing Among Women With HIV
Cervical cancer is the second most common type of cancer among women worldwide. Women with
human immunodeficiency virus (HIV) bear a disproportionate burden of cervical cancer and its
precursor, cervical intraepithelial neoplasia (CIN), that result from persistent high-risk
Human Papillomavirus (HPV) infection. HIV clinical practice guidelines recommend two Pap
tests in the year following diagnosis, and if both are normal, yearly thereafter. Nationally,
only 25% of women meet this recommendation. The mean annual Pap testing rate for federally
funded HIV centers is only 55.7%. In 2009, quality improvement statistics from the Johns
Hopkins Hospital Moore Clinic, a large urban HIV center, revealed an annual Pap testing rate
of 59%. This occurred despite interventions to address adherence issues were implemented,
including nurse case management, co-location of HIV and gynecology services, flexible
scheduling, and continuity of care. Women keep their appointments for HIV primary care more
often than for gynecology care in the Moore Clinic, so an intervention that takes place
during a primary care visit could improve cervical cancer screening rates.
The availability of HPV testing provides a unique opportunity to increase perceived
susceptibility to and severity of cervical cancer among women with HIV, and to encourage
follow-up Pap testing. HPV testing involves analyzing a sample of cervicovaginal cells for
the presence of high-risk HPV strains. Detection of high-risk strains of the virus indicates
a high risk for high grade CIN and cancer, while a negative HPV test predicts a less than 2%
risk of developing CIN. HPV testing can be easily conducted by women themselves through
self-collection in a primary care visit. Studies of women without HIV who do not have regular
Pap testing have demonstrated that self-collected HPV testing and results counseling
increases the overall screening rate, and women who test positive for HPV have a high rate of
follow-up Pap testing. Self-collected HPV testing and results counseling could be utilized in
the HIV primary care setting to promote Pap testing among women with HIV.
This study is a randomized trial to test whether receiving self-collected HPV testing and results counseling in HIV primary care will increase completion of Pap testing in a group of women attending the Johns Hopkins Hospital Moore Clinic for HIV Care. The study is informed by the Health Belief Model (HBM), which posits that screening behavior will increase if persons at risk for disease have a cue to action that increases their perception of susceptibility to and severity of the disease. In this study, the HPV test and results counseling are cues to action that also correctly identify those women at high risk for disease. To achieve these aims, 111 women who are late for Pap testing will be recruited for participation while they are at an HIV care appointment. They will be randomized to HPV self-collection and results counseling, or to receive usual care. Six months after enrollment, medical records will be reviewed for completion of Pap testing in the intervening months. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT02135419 -
Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions
|
Phase 3 | |
| Active, not recruiting |
NCT02663856 -
My Smart Age With HIV: Smartphone Self-assessment of Frailty
|
||
| Completed |
NCT02663869 -
Aging With HIV at Younger vs Older Age: a Diverse Population With Distinct Comorbidity Profiles
|
||
| Terminated |
NCT02743598 -
Liraglutide for HIV-associated Neurocognitive Disorder
|
Phase 4 | |
| Completed |
NCT02846402 -
Impact of HIV Self-testing Among Female Sex Workers in Kampala, Uganda
|
N/A | |
| Completed |
NCT02921516 -
Growing Up: Intervening With HIV-Positive Adolescents in Resource-Poor Settings
|
N/A | |
| Completed |
NCT02659306 -
Metformin Immunotherapy in HIV Infection
|
Phase 1 | |
| Completed |
NCT02564341 -
Targeting Effective Analgesia in Clinics for HIV - Intervention
|
N/A | |
| Active, not recruiting |
NCT02302950 -
A Retrospective Analysis of Raltegravir Use in Minority HIV Infected Women in Houston, Texas
|
N/A | |
| Terminated |
NCT02109224 -
Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection
|
Phase 1 | |
| Terminated |
NCT01902186 -
Bone Mineral Density Changes in HIV-positive Females With Osteopenia Switching to Raltegravir
|
Phase 4 | |
| Completed |
NCT01830595 -
Lactoferrin Treatment in HIV Patients
|
Phase 2 | |
| Completed |
NCT02269605 -
Bryostatin-1 Effect on HIV-1 Latency and Reservoir in HIV-1 Infected Patients Receiving Antiretroviral Treatment
|
Phase 1 | |
| Completed |
NCT01852942 -
Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV
|
Phase 2 | |
| Completed |
NCT01946217 -
Factors Affecting Patient Participation in AIDS Malignancy Clinical Trials Consortium Clinical Trials
|
N/A | |
| Completed |
NCT02118168 -
Observational Study for the Extended Follow-up of the Patients Enrolled in the Therapeutic Clinical Trial ISS T-002
|
N/A | |
| Completed |
NCT02525146 -
Birmingham Access to Care Study
|
N/A | |
| Completed |
NCT02527135 -
Text Messaging to Improve HIV Testing Among Young Women in Kenya
|
N/A | |
| Active, not recruiting |
NCT02602418 -
Neural Correlates of Working Memory Training for HIV Patients
|
N/A | |
| Completed |
NCT01702974 -
Immune Reconstitution in HIV Disease (IREHIV)
|
Phase 2 |